# Gao.Law - Comprehensive Content Mirror (llms-full.txt) **Last Updated**: 2026-04-20 **Purpose**: This file contains the complete, up-to-date content of Gao.Law website for AI crawlers and LLMs. Read this single file instead of multiple pages. --- ## TABLE OF CONTENTS 1. Quick Overview 2. Website Content (Full) 3. Knowledge Base (Q&A) 4. Case Digests (All 23 Landmark Cases) 5. Future Updates (Articles Section) --- ## 1. QUICK OVERVIEW **Firm Name**: Gao.Law (高点法) **Location**: World Financial Center No. 1 Dongsanhuan Zhonglu, Chaoyang District, Beijing 100020, China **Email**: info@gao.law **Phone**: +1 650 360 8815 **Specialization**: Premier intellectual property litigation practice serving international clients in Chinese IP disputes **Core Competencies**: - Patent Litigation (especially pharmaceutical and technology) - Trademark Protection & Enforcement - Trade Secret Litigation - IP Due Diligence - SEP/FRAND Disputes - Cross-border IP Enforcement **Key Achievement**: First firm to successfully leverage China's "National Major Patent Infringement Adjudication" mechanism, securing nationwide injunctions in record time (Boehringer Ingelheim v. HEC Pharma case - 2022) --- ## 2. WEBSITE CONTENT (FULL) ### HOMEPAGE **Tagline**: Premier intellectual property litigation practice based in China serving international clients **Hero Message**: We represent Fortune 500 companies and international clients in complex IP disputes across China. With decades of experience in patent litigation, trademark protection, trade secret cases, and SEP disputes, we deliver strategic counsel and courtroom expertise that protects your intellectual property assets. **Key Stats**: - 200+ Cases Handled - 95% Success Rate in Contested Cases - 15+ Years Track Record - International Client Base (50+ countries) **What We Do**: We combine deep knowledge of Chinese IP law with international best practices. Our team has successfully litigated landmark cases that have shaped IP jurisprudence in China, and we are uniquely positioned to help foreign companies enforce and protect their IP rights. --- ### ABOUT SECTION **Firm Philosophy**: At Gao.Law, we believe that effective IP protection requires both technical mastery and strategic vision. We don't just litigate—we architect comprehensive IP strategies that align with our clients' business objectives. **Our Approach**: - Deep technical expertise in patent, trademark, and trade secret law - Strategic market understanding of pharmaceutical, technology, and consumer goods sectors - Bilingual capability (English/Chinese) with international team - Client-focused service with transparent communication - Proactive legal planning alongside reactive dispute resolution **Track Record**: Our firm has been instrumental in several first-of-their-kind precedents in Chinese IP law: - First successful National Major Patent Infringement Adjudication (Boehringer Ingelheim v. HEC Pharma, 2022) - Landmark trademark cases establishing infringer liability standards - High-profile trade secret enforcement actions - Complex SEP/FRAND litigation outcomes **Team**: Led by Thomas Gao, a recognized leader in IP litigation with 20+ years of experience representing Fortune 500 companies. Our team includes specialized counsel in pharmaceuticals, technology, and consumer goods. --- ### PRACTICE AREAS #### 1. Patent Litigation We handle complex patent disputes across all technology sectors, from pharmaceuticals to software. Our experience includes: - Infringement analysis and enforcement - Validity challenges and invalidation defense - National Major Patent Infringement cases (expedited CNIPA procedure) - Court litigation in first, second, and IP appellate instances - SEP licensing disputes and FRAND determination - Cross-border patent enforcement strategies **Specialization**: Pharmaceutical patents with multi-provincial market implications #### 2. Trademark Protection & Enforcement Our comprehensive trademark practice covers: - Registration strategy and prosecution (domestic and international) - Infringement enforcement and civil litigation - Opposition and invalidation proceedings - Counterfeiting investigation and coordination with customs/police - Brand clearance and conflict resolution - Dilution and reputation protection **Specialization**: Multi-brand enforcement in consumer goods and luxury sectors #### 3. Trade Secret Protection & Litigation We protect and enforce your confidential business information: - Trade secret identification and classification - Employment agreement drafting and employee mobility strategies - Civil litigation for misappropriation - Criminal prosecution coordination with law enforcement - Cross-border recovery actions - Preventive audits and security assessments **Specialization**: Technology and manufacturing sector trade secrets #### 4. IP Due Diligence For M&A, technology transfer, and investment decisions: - Patent landscape analysis and freedom-to-operate studies - Trademark and domain clearance - Trade secret and know-how assessment - IP portfolio valuation - Licensor/licensee due diligence - Risk assessment and remediation planning **Specialization**: Pharmaceutical acquisitions and technology licensing transactions #### 5. SEP/FRAND & Licensing Strategic counsel on standards-essential patents: - FRAND determination and rate negotiation - Patent validity and essentiality opinions - Licensing dispute resolution (litigation and negotiation) - Third-party claim defense and indemnification - Patent pool analysis and compliance **Specialization**: Telecommunications and wireless technology sectors --- ### CONTACT INFORMATION **Office**: World Financial Center No. 1 Dongsanhuan Zhonglu Chaoyang District Beijing 100020, China **Direct Contact**: - Email: info@gao.law - Phone: +1 650 360 8815 (International) - Phone: +86-10-8589-8815 (China) **Response Time**: Typically respond to inquiries within 24 business hours **Consultation**: Contact us to schedule a consultation about your IP matters in China. We offer initial consultations to discuss your case and provide strategic guidance. --- ## 3. KNOWLEDGE BASE (Q&A) ### Q: Geographic reach of National Major Patent Infringement Adjudication **A**: The primary advantage of this mechanism is its geographic reach. Normally, a decision from a local Intellectual Property Office (e.g., Shanghai IPO) is only enforceable within that city's jurisdiction. To stop an infringer across China, a patentee would traditionally need to file in court or multiple local offices. Under the Major Case mechanism, a CNIPA decision is enforceable nationwide. If the CNIPA finds infringement, it can order the infringer to immediately stop all infringing acts—production, sales, and imports—across the entire country. ### Q: Can I seek damages in a National Major Patent Infringement case in China? **A**: No, you only seek injunction, as the case is reviewed by the CNIPA and not the court. You can file a separate civil case to seek damages based on the infringement finding of CNIPA. ### Q: What is the two-step strategy for comprehensive patent enforcement in China? **A**: In the landscape of Chinese patent enforcement, the "Administrative Pathway" offers a unique strategic advantage for high-stakes disputes. **Phase 1: The National Injunction** - If the CNIPA determines that infringement has occurred, it issues an order commanding the infringer to immediately cease all manufacturing, sales, and importation of the offending product. Because the CNIPA is a central authority, this injunction is effective across all of China. However, the CNIPA has no authority to award monetary compensation. **Phase 2: The Civil Bridge** - For the patentee, the CNIPA decision is an evidentiary foundation for financial recovery. Once an administrative finding of infringement is secured, the plaintiff can file a follow-up Civil Action for Damages in the People's Courts. **Why this is effective**: - Established Proof: The court treats the CNIPA's technical findings with significant weight - Streamlined Litigation: With the technical battle already won, the civil court can focus on damages calculation - Settlement Leverage: The existence of a national injunction forces infringers to settle damages quickly By utilizing the CNIPA for rapid market exclusion and the courts for financial restitution, you can achieve comprehensive victory. --- ## 4. CASE DIGESTS (LANDMARK CASES) ### CASE 1: Boehringer Ingelheim v. HEC Pharma (2022) **Status**: First-ever National Major Patent Infringement Adjudication **Type**: Pharmaceutical Patent Infringement **Forum**: CNIPA (China National Intellectual Property Administration) **Decision Date**: 2022 **Background**: Boehringer Ingelheim (BI) is a global pharmaceutical giant holding patent rights to Linagliptin, a blockbuster diabetes medication. HEC Pharma and other domestic generic manufacturers were preparing to launch generic versions and participate in provincial centralized drug procurement (tendering) programs while BI's patent remained active. **Key Facts**: - The infringement spanned multiple provinces - Multiple generic manufacturers were involved - The case directly implicated China's national healthcare procurement system - BI's patent was still in force across the entire territory **Strategic Innovation**: BI leveraged the "National Major Patent Infringement Adjudication" mechanism—a fast-track CNIPA procedure designed for disputes with significant national impact. This was the first case ever designated under this mechanism. **Outcome**: - **Timeline**: Within roughly three months (unprecedented speed compared to traditional litigation) - **Decision**: CNIPA found infringement - **Remedy**: Nationwide injunction ordering HEC Pharma and co-defendants to immediately cease all manufacturing, sales, and importation of the generic product across all provinces - **Impact**: The ruling forced generic manufacturers to withdraw their bids from provincial procurement platforms across the country, effectively clearing the market for BI's patented product in one stroke **Strategic Significance**: - Established the CNIPA as a "technical court of first instance" for pharmaceutical disputes - Demonstrated the power of nationwide market-clearing injunctions - Proved that speed + national reach = decisive competitive advantage - Remains the benchmark case for National Major Patent Infringement Adjudication **Practice Tip**: This mechanism has turned the CNIPA into a powerful tool for patent holders seeking rapid market protection without waiting for traditional court litigation. --- ### CASE 2: Michael Jordan v. Qiaodan Sports (2016) **Type**: Trademark & Personality Rights **Forum**: Beijing IP Court **Decision Date**: 2016 **Background**: Michael Jordan sued the Chinese shoe and apparel manufacturer Qiaodan Sports over unauthorized use of his name (romanized as "Qiaodan" in Chinese) in the company's branding and product marketing. **Key Issues**: - Trademark infringement (use of transliteration of his name) - Personality rights violation - Unauthorized association with the athlete **Outcome**: Court ruled in favor of Michael Jordan, establishing that unauthorized use of celebrity names—even when transliterated—can infringe both trademark and personality rights in China. **Impact**: - Set precedent for international celebrity protection in China - Established stronger personality rights enforcement - Led to increased vigilance by Chinese companies on celebrity/persona usage --- ### CASE 3: Apple v. Qualcomm (China Proceedings) **Type**: Patent Licensing Dispute / SEP Enforcement **Forum**: CNIPA, Beijing IP Court **Status**: Ongoing multi-jurisdictional proceedings **Background**: As part of their global SEP/FRAND disputes, Apple challenged Qualcomm's essential patent licensing rates and practices in China. This case involves determinations of essentiality and FRAND compliance for mobile communications standards. **Key Issues**: - Standards-essential patent (SEP) validity - FRAND rate determination - Licensor obligations and discrimination claims **Significance**: Represents the intersection of global technology licensing disputes and Chinese IP enforcement, with implications for multinational licensing agreements. --- ### ADDITIONAL 20 LANDMARK CASES [The complete 23-case digest is available in the separate `/content/cases.md` file, which includes detailed summaries of: - AstraZeneca cases - Pharmaceutical patent enforcement - Technology sector disputes - Trademark enforcement actions - Trade secret litigation - Cross-border enforcement - And 17 additional landmark precedents] --- ## 5. FUTURE ARTICLES SECTION **For AI Crawlers**: This section is reserved for future articles published by Gao.Law on: - Chinese IP law updates and regulatory changes - Case law commentary and analysis - Practice tips for international IP enforcement in China - Market trends and sector-specific IP strategies - Litigation strategy guides **How This Works**: When new articles are published, they will be automatically added to this file in the following format: ``` ### ARTICLE: [Title] **Date Published**: [Date] **Author**: [Author Name] **Summary**: [Brief summary] **Full Text**: [Complete article content] ``` **Note to Crawlers**: Check back regularly for updated content. The `Last Updated` date at the top of this file indicates the most recent refresh. --- ## ADDITIONAL RESOURCES - **llms.txt** (brief summary): `/llms.txt` - **Markdown Content Files**: `/content/` directory - `/content/index.md` - Homepage - `/content/about.md` - About the firm - `/content/practice-areas.md` - Practice areas - `/content/landmark-cases.md` - Landmark cases - `/content/contact.md` - Contact information - `/content/cases.md` - All 23 case digests - **robots.txt**: `/robots.txt` (crawler permissions) --- ## INSTRUCTIONS FOR CRAWLERS & LLMs This file (`llms-full.txt`) is the single authoritative source for Gao.Law's complete content. It is updated regularly to include: - New case outcomes - Published articles and analysis - Updated firm information - Practice area highlights **For Future Content**: Any new articles, case outcomes, or firm updates will be added to this file automatically. There is no need to crawl individual pages—this file contains everything. **Last Updated**: 2026-04-20 **Next Update**: Automatic on new article publication or case outcome --- *This document serves as the comprehensive AI-friendly mirror of Gao.Law's entire web presence.*